BioSpace News Archive

Zenas BioPharma announced the submission of an investigational new drug application to the China National Medical Products Administration for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease.

Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® in combination with carfilzomib and dexamethasone demonstrated a median progression free survival of 35.7 months, compared to 19.2 months in patients treated with Kd alone, as evaluated by an Independent Review Committee.

Kintor Pharmaceutical Limited announced that the company’s stock has been included in the MSCI China Index, effective May 31, 2022.

Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced new analyses from the Phase 3 EMPOWUR Extension Study of GEMTESA, presented Sunday at the 2022 annual meeting of the American Urological Association.

Orphazyme A/S in restructuring, a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C, announces that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc.

KemPharm, Inc. announced a definitive agreement with Orphazyme A/S to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein amplifier being developed as a treatment for Niemann-Pick disease type C.